CALRLong36 peptide (Herlev Hospital)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCALRLong36 peptide (Herlev Hospital)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionT-cell surface antigen CD4 inhibitors
TargetsT-cell surface antigen CD4
Therapy Area/IndicationsMyeloproliferative Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesHerlev Hospital
China Registration ClassN/A

Develop Information

Active CompaniesHerlev Hospital
Inactive CompaniesN/A
Active IndicationsMyeloproliferative Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A